ResearcherMedical College of WisconsinActive in the last 2 years
Daniel Dorbin
Matched on ORCID iD 0000-0003-2484-7102; OpenAlex author ID A5120125715. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2026: 2 papers
Papers 2
- Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
- Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-1181↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nikki K. Lytle · 2 shared papers, 2026 · strength 0.41
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
- Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
- Yongwoo David Seo · 2 shared papers, 2026 · strength 0.41
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
- Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
- Mohammed Aldakkak · 2 shared papers, 2026 · strength 0.41
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
- Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
- Douglas B. Evans · 2 shared papers, 2026 · strength 0.41
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
- Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
- Thomas B. McFall · 2 shared papers, 2026 · strength 0.41
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
- Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
- Susan Tsai · 2 shared papers, 2026 · strength 0.41
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
- Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
- G. Aaron Hobbs · 2 shared papers, 2026 · strength 0.41
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
- Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
- Mandana Kamgar · 2 shared papers, 2026 · strength 0.41
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
- Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
- Razelle Kurzrock MD · 2 shared papers, 2026 · strength 0.41
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
- Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
- William Adrian Hall · 1 shared paper, 2026 · strength 0.21
- Rachel A. Burge · 1 shared paper, 2026 · strength 0.21
- Sam Z. Thalji · 1 shared paper, 2026 · strength 0.21
- Ben George · 1 shared paper, 2026 · strength 0.21
- Beth E. Erickson · 1 shared paper, 2026 · strength 0.21
- Channing J. Der · 1 shared paper, 2026 · strength 0.21
- Kathleen K. Christians · 1 shared paper, 2026 · strength 0.21
- Brian F Volkman · 1 shared paper, 2026 · strength 0.20
- Christabelle Rajesh · 1 shared paper, 2026 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.